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Fibroblast growth factor-2 (FGF2) and syndecan-1
(SDC1) are potential biomarkers for putative
circulating CD15+/CD30+ cells in poor outcome
Hodgkin lymphoma patients
Rajendra Gharbaran1, Andre Goy1, Takemi Tanaka2, Jongwhan Park1, Chris Kim1, Nafis Hasan2, Swathi Vemulapalli1,
Sreeja Sarojini1, Madalina Tuluc2, Kip Nalley3, Pritish Bhattacharyya1, Andrew Pecora1 and K Stephen Suh1*

Abstract
Background: High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary
refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of
patients, we investigated both tumor biopsies and peripheral blood leukocytes (PBL) of untreated (chemo-naïve,
CN) Nodular Sclerosis Classic Hodgkin Lymphoma (NS-cHL) patients for consistent biomarkers that can predict the
outcome prior to frontline treatment.
Methods and materials: Bioinformatics data mining was used to generate 151 candidate biomarkers, which were
screened against a library of 10 HL cell lines. Expression of FGF2 and SDC1 by CD30+ cells from HL patient samples
representing good and poor outcomes were analyzed by qRT-PCR, immunohistochemical (IHC), and
immunofluorescence analyses.
Results: To identify predictive HL-specific biomarkers, potential marker genes selected using bioinformatics
approaches were screened against HL cell lines and HL patient samples. Fibroblast Growth Factor-2 (FGF2) and
Syndecan-1 (SDC1) were overexpressed in all HL cell lines, and the overexpression was HL-specific when compared
to 116 non-Hodgkin lymphoma tissues. In the analysis of stratified NS-cHL patient samples, expression of FGF2 and
SDC1 were 245 fold and 91 fold higher, respectively, in the poor outcome (PO) group than in the good outcome
(GO) group. The PO group exhibited higher expression of the HL marker CD30, the macrophage marker CD68, and
metastatic markers TGFβ1 and MMP9 compared to the GO group. This expression signature was confirmed by
qualitative immunohistochemical and immunofluorescent data. A Kaplan-Meier analysis indicated that samples in
which the CD30+ cells carried an FGF2+/SDC1+ immunophenotype showed shortened survival. Analysis of
chemo-naive HL blood samples suggested that in the PO group a subset of CD30+ HL cells had entered the
circulation. These cells significantly overexpressed FGF2 and SDC1 compared to the GO group. The PO group
showed significant down-regulation of markers for monocytes, T-cells, and B-cells. These expression signatures were
eliminated in heavily pretreated patients.
Conclusion: The results suggest that small subsets of circulating CD30+/CD15+ cells expressing FGF2 and SDC1
represent biomarkers that identify NS-cHL patients who will experience a poor outcome (primary refractory and
early relapsing).
Keywords: Hodgkin lymphoma, Predictive biomarkers, Relapse, Refractory, Circulating tumor cells, Clinical outcome
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Background
Up to 20% of Hodgkin lymphoma (HL) patients are
either refractory to treatment (primary refractory) or experience relapse within four years (early relapse) of
achieving complete remission (CR), and includes patients who experience progressive disease and patients
with a particularly poor prognosis for other reasons [1].
Only half of HL patients survive for two years if
front line therapy fails, and autologous hematopoietic
stem-cell transplant (ASCT) is only 50% curative [2].
Although the International Prognostic Score was introduced to improve the risk stratification of patients [3],
its applicability is limited for predicting high risk cHL
patients, regardless of clinical stage. While patients in
this group may benefit from analysis of the tumorassociated macrophage marker CD68, which can be
used to predict adverse outcomes of cHL [4], the prediction is controversial [5]. The antibody conjugate drug
brentuximab vedotin targets CD30. In clinical trials,
brentuximab vedotin therapy improved clinical outcomes
for relapsing and refractory classical HL (RR-cHL) patients
by producing survival times that were 6 months longer
than for patients on the conventional treatment arm [6].
This increased survival could perhaps be due to increased chemoresistance that can result from heavy pretreatment. Therefore, the availability of biomarkers that
identify patients who will have a poor outcome to conventional frontline therapy will permit more aggressive
treatment of these patients, improving their prognosis.
Classical HL is a monoclonal lymphoid neoplasm that
in almost all instances appears to be derived from
(post-) germinal center B cells [7-9]. The immunohistochemical (IHC) hallmark of HL tumor cells is CD30
antigen expression [10]. The morphological phenotype
of cHL comprises an unusually small number (<2%) of
mononuclear Hodgkin (H) cells and multinucleated
Reed-Sternberg (RS) cells residing in an extensive
inflammatory background, which is mostly composed of
T cells, histocytes, eosinophils, plasma cells, and macrophages [10]. This inflammatory background in the tumor
microenvironment is maintained by Hodgkin’s and
Reed-Sternberg cell (HRS)-derived chemokines and cytokines that recruit the tumor microenvironment cellular
components [11-14]. The composition of the tumor
microenvironment or the molecular phenotype of the
HRS cells, or both, is thought to determine the relative
aggressiveness of cHL at an individual level [10].
At presentation, about 10–15% of cHL cases have
extranodal involvement [15], which is a negative prognostic factor even for patients with limited stage disease [16].
Extranodal involvement, whether primary or secondary,
indicates lymphatic and hematogenous spread of the
disease [15]. Therefore, neoplastic HRS cells could reasonably be assumed to occur in peripheral blood, albeit at
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levels not detectable by present diagnostic techniques,
thus resulting in circulating tumor cell (CTC) involvement
in HL. CTCs are frequently associated with poor clinical
outcomes for solid [17] and liquid tumors [18]. Despite
the limited number of cases (about a dozen over the past
100 years) of CTCs in the peripheral blood of HL patients,
most were associated with either primary refractory or relapsing disease. In addition, well-established cell lines that
have contributed tremendously to the understanding of
HL were derived from primary HL tumor cells isolated
from extranodal sites: peripheral blood [19], bone marrow
[20], or pleural fluid [21] of refractory or relapsing
patients. These findings suggest that primary HL tumor
cells can escape the physical barrier of the tumor microenvironment into the circulation to access extra-nodal
destinations. The limited evidence indicating the presence
of HRS cells among peripheral blood leukocytes (PBL)
may be a consequence of their low proliferative index, the
terminally differentiated status of the RS cells and their
lack of mobility, or the propensity of these malignant cells
to form a solid tumor mass [22]. These characteristics
have hampered investigations aimed at identifying HRSderived biomarkers in peripheral blood for high risk, poor
outcome, primary refractory, and early relapsing cHL
patients.

Results
Characteristics of clinical samples

The characteristics for clinical samples for PBL are listed
in Table 1. Retrospective clinical samples of PBL collected
from 25 NS-cHL patients (average age: 34.48 years, range:
20–79, 13 females and 12 males) were categorized into
three groups mainly on the basis of their response to
frontline therapy: 1) good outcome pre-therapy: chemo-na
ïve relapse free/progression-free survival > 4 years (GO,
n=12); 2) poor outcome pre-therapy: chemo-naïve primary refractory or early relapsing (PO(CN), n=6; 3) poor
outcome post-therapy: chemo-exposed, multiple relapse
within 4 years (PO(CE), n=7). Among the pre-therapy,
chemo-naïve patients (n=18), 68% were diagnosed during
early disease stages (I and II), 10% (n=2) at stage III, and
15% (n=3) at stage IV. Of the early stage diagnoses (I and
II, n=13), more than 30% (n=4) were either primary
refractory or developed early relapses shortly after frontline therapy. The remaining PO(CN) samples were from
advanced stages (III & IV). Also, 56% (n=14) of the
patients were younger than the average age (34.48 years)
at diagnosis.
Bioinformatics and data mining for potential biomarkers

To enhance the specificity of potential poor outcome
biomarkers, a bioinformatics based approach was used.
Potential biomarkers for HL were selected from the
Cancer Gene Index and screened using a library of HL
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Table 1 Patient characteristics for each clinical outcome group
Donors Sex

Clinical diagnosis
Subtype Bulky/
non-bulky

Age Stage at
diagnosis

Outcome
Treatment

Good
GO1
outcome
GO2

F

NS

UNSP

29

IV

ABVD

PFS

F

NS

B

41

IIA

Stanford V + Rad

PFS

GO3

F

NS

NB

79

IA

ABVD + Rad

PFS

GO4

F

NS

B

22

IIA

Stanford V + Rad

PFS

GO5

M

NS

NB

43

IIA

ABVD

PFS

GO6

M

NS

B

20

IIA

ABVD+R

PFS

GO7

F

NS

NB

64

IIA

ABVD

PFS

GO8

F

NS

B

51

IIIB

ABVD + Rad

PFS

GO9

F

NS

UNSP

54

IV

ABVD

PFS

GO10

F

NS

UNSP

22

IIA

ABVD

PFS

GO11

F

NS

NB

25

IIA

ABVD

PFS

GO12

F

NS

NB

26

IIB

ABVD

PFS

Poor
PO1
outcome
PO2
(CN)

M

NS

UNSP

48

IIA

ABVD+R (1); R+Bendamustine (2) Zevalin(3)

Rel.

M

NS

B

24

II

ABVD (1); acc. BEACOPP (4X) std BEACOPP (2X)(2);
Bendamustine + R (3); IGEV + Rad (4); BCPAT (5); CR PT

Ref.

PO3

M

NS

UNSP

25

IIB

ABVD (1); ICE X 3 followed by BPCAT +Local Rad (2); CR PT

Rel.

PO4

F

NS

B

25

IIA

ABVD (1); ICE (2X) (2); GVD+R+Rad (3); HCVAD 1A (4);
F+ECPOCH TH2 Allogenic (5); CR PT

Ref.

PO5

M

NS

B

49

IV

ABVD + R (1); ICE + R followed by BCPAT (2); R for EBV
reactivation (3); CR PT

Ref.

PO6

M

NS

NB

20

IIIB

ABVD+R (1); ICE X2 (2); IGEV+R × 2 (3); Rad (4); BCPAT (5); CR

Ref.

Poor
PO1
outcome
(CE)
PO2

M

NS

UNSP

31

IIIB

ABVD (1); ABVD (2); CPPV (3); DICE followed by BPCAT (4);
HCVAD 1A + 1B (5); FMPAL (5)

Rel.

F

NS

UNSP

23

II

MOPP+ABVD (1); BEAC conditioning pre auto transplant (2);
Rad (3); ICE X 2/ESHAP X 6 (4);

Rel.

PO3

M

NS

UNSP

21

II

ABVD (1); ESHAP x 1 followed by BCPAT (2); Gemcitabine +
Navelbine (3); HCVAD X 3A’S followed by FMPAL (4);
DLI infusion (5); Revlamid+DLI infusion (6);

Rel.

PO4

F

NS

B

20

IIA

ABVD+Rad (1); ICE+ auto transplant (2); bone resection+Rad (3);
WU protocol phase II Revlamid (4); TH2 Study (EPOCH+FR) NCI
protocol followed by BEACOPP pre transplant (5); (No rel.)

Rel.

PO5

M

NS

UNSP

30

IIB

ABVD + Rad (1); ICE + Gemzar followed by BPCAT (2); ESHAP X 3 (3);
HCVAD X 5 followed by FMPAL (4); Bendamustine (SK Protocol)
08–041 (5)

Rel.

PO6

M

NS

UNSP

49

IIIB

ABVD (1); ICE followed by BCPAT; GVD + R (3); Revlamid (4) SGN-40 × Rel.
2 cycles (5); (PD)

PO7

M

NS

UNSP

21

IIA

ABVD (1); ESAHP (2); IGEV (3); BEAC + Rad (4); GDP; R+MOPP (5);
died of PD.

cell lines. Bioinformatics-guided approaches have the
unique advantage of avoiding challenges that arise
from the cost, time, and labor that are required to
identify potential biomarkers for human diseases. The
BioXM software platform (Sophic Alliance, Rockville,
MD) was used to mine published data for more than
7,000 cancer genes and 2,200 biomarker genes. These
genes were annotated and validated from 18 million

Rel.

Medline abstracts and 24,000 HUGO genes using a
combination of algorithmic methods (Biomax Informatics, Munich, Germany), including natural language processing (NPL), Biomarker Role Codes, the
NCI Cancer Thesaurus, and Karp’s Evidence Codes
[23]. Compilation of the outputs resulted in the
identification of 151 candidate HL biomarker genes
(Table 2).
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Table 2 HL-relevant genes identified by bioinformatics data mining
ABCC2

CCR4

CHEK2

ESR2

HSPA8

MALT1

OGG1

SPN

ABL1

CCR7

CLU

EZH2

HYAL2

MLL

PAX5

SRC

ADA

CD14

CNR1

FAS

ICAM1

MME

PDCD1LG2

SST

ADIPOQ

CD2

COL18A1

FCER2

ID2

MPO

PIK3CA

STAT6

AR

CD22

CP

FCGR3A

IFNG

MS4A1

PIM1

TBX21

ATF3

CD27

CR2

FGF2

IGHE

MSH6

PLK1

TERF1

B2M

CD28

CSF3

FHIT

IGLα

MUC16

POU2F2

TRFC

B3GAT1

CD34

CTLA4

FLT3

IL2

MYB

PRL

TGFB1

BCL10

CD38

CXCL10

FSCN1

IL2RA

MYC

PTEN

TIA1

BCL3

CD44

CXCR3

GATA3

IL3

MYOD1

PTH

TNFRSF1β

BCL6

CD46

CXCR4

GFAP

IRF4

NAT2

REL

TNFSF13β

BIC

CD5

CYP17A1

GGT1

ITGA4

NBN

S100A6

TP63

BMI1

CD52

CYP3A43

GHRL

ITGAL

NF1

SDC1

TRAF1

BSG

CD55

D13S25

GPX1

ITGB2

NME1

SELL

TRGα

CASP8

CD59

DUT

HLA-A

JUNB

NOS2

SERPINE1

TSHB

CCL17

CD70

E2F1

HMGB1

LDHA

NPM1

SERPING1

VEGFA

CCL5

CD79A

E2F3

HP

LEP

NPY

SMARCB1

WT1

CCND1

CDC25A

EDN1

HSPA1A

LEPR

NRAS

SOCS1

ZBTB16

CCND3

CDK4

ERBB2

HSPA4

MAL

NTRK2

SPI1

The clinical outcome of HL patients is not associated with
tumor staging, age, bulkiness or frontline therapy

Contingency analyses of 25 NS-cHL patients did not
identify associations between clinical outcomes (good
outcome (GO), n=12, vs. poor outcome (PO), n=13)
and major clinical characteristics such as clinical stage
(p > 0.4), age group (p > 0.11), bulky disease (with or

without inclusion of unspecified data, p > 0.18), and
frontline therapy (p > 0.27) (Figure 1, Table 1). The
same analysis of the dataset with the PO(CE) group
excluded also failed to identify any relationship between outcome and clinical phenotype. This result differs from established trends used in stratification
schemes of current prognostic scoring systems. Our

Figure 1 Lack of association between clinical outcome and tumor staging, age, bulkiness, or frontline therapies and the
overexpression of FGF2 and SDC1 by HL cell lines. Contingency analysis was performed against major clinical characteristics (y-axis, right
column) including tumor stage (p > 0.4), age group (p > 0.11), bulkiness of the disease (p > 0.18), and frontline therapies used (p > 0.27) for HL
patients with good outcome (GO) vs. poor outcome (PO) (x-axis). The percentage of each clinical characteristic within each group is indicated.
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results suggest that alteration of specific molecular
signaling may contribute to clinical outcome.

group is a consequence of increased numbers of
CD30+ cells rather than of CD20+ B-cells.

FGF2 and SDC1 are overexpressed by HL cell lines and by
CD30+ cells in the poor outcome group of HL patients

CD30+ cells coexpress FGF2 and SDC1 in macrophage-rich
tissues from the poor outcome group of HL patients

Established HL cell lines potentially represent poor outcome HL because they were generated from primary
HRS cells isolated from extranodal sites of pleural effusion, bone marrow, or peripheral blood. Extranodal HL
implies lymphatic and hematogenous dissemination via
circulation. We screened ten HL cell lines for altered
expression of a set of bioinformatics-identified genes
representing multiple signaling pathways such as apoptosis, proliferation, angiogenesis, and metastasis (Table 2).
The qRT-PCR results revealed that, compared to their
expression by primary B cells, FGF2 (Fibroblast Growth
Factor 2) and SDC1 (Syndecan1) were overexpressed in
eight of the ten cell lines (Figure 2A).
To determine whether FGF2 and SDC1 were
overexpressed specifically in HL patient samples, 48
HL and 116 major subtypes of non-Hodgkin lymphoma
(NHL) tissue sections in a tissue microarray format
were analyzed by immunohistochemical methods
(Figure 2B). Qualitative scoring of immunostaining
showed that FGF2 and SDC1 were predominantly
overexpressed in HL compared to NHL or normal
lymph nodes (p < 0.05). To investigate the gene expression profile of FGF2 and SDC1 in HL tissues, 67
archived HL samples with clinical outcome data were
analyzed by qRT-PCR and immunohistochemical methods. The PCR data showed that, when compared to
normal lymph node controls, all HL tissues overexpressed FGF2 and SDC1, but tissues from poor outcome patients (n=9) showed 246- and 91-fold increases
in FGF2 and SDC1 levels, respectively, while tissues
from good outcome patients (n=20) had only 10- and 2fold respective increases. Thus, the poor outcome group
expressed 24-fold more FGF2 and 56-fold more SDC1
than the good outcome group (Figure 2C). Expression
of CD30 was increased by 59-fold in the poor outcome
group and 3-fold in the good outcome group, suggesting
that the fold-difference between the poor and good outcome groups is largely contributed by CD30 positive
(CD30+) cells in the poor outcome group. Immunostaining of FGF2 and SDC1 was intense in the poor outcome group but weak to moderate in the good outcome
group (Figure 2D). In HL tissues from the poor outcome group, CD30+FGF2+SDC1+ cells were seen in
clusters in whole mount HL tissues (data not shown).
Immunostaining of the same tissues indicated that
CD20 expression was significantly reduced in all HL
tissues compared to normal controls (Figure 2E),
suggesting that the increase in staining and gene expression of FGF2 and SDC1 in the poor outcome

Double immunofluorescence analysis of HL tissues
showed that all sections from the poor outcome group
had clusters of CD30+ cells that coexpressed FGF2 or
SDC1 (Figure 3A). The majority of tissues showed weak
or no FGF2 or SDC1 staining or weak staining for both
FGF2 and SDC1 (Figure 3B graph). All FGF2+/SDC1+
cells with intense fluorescence (n=6) were associated
with the poor outcome group, and often clustered in
several regions within the whole mount HL tissues.
Clusters of FGF2-/SDC1+ and FGF2+/SDC1- cells
were seen in each of the remaining poor outcome
HL tissues (n=3). Also, clusters of FGF2+/SDC1- or
FGF-/SDC1- cells were seen in good outcome HL tissues (Figure 3B-graph). These results suggest that FGF2
and SDC1 coexpression in CD30+ cells or in clusters of
cells may trigger molecular signaling that contributes to
a poor clinical outcome. A Kaplan-Meier analysis also
indicated that the FGF2+/SDC1+ immunophenotype of
CD30+ cells is associated with shortened survival
(not shown).
CD68+ tumor-associated macrophages were recently
shown to be associated with adverse outcomes, including
shortened survival [24], which is a consequence of primary refractory and early relapsing cHL. Therefore, we
evaluated the number of CD68+ tumor-associated macrophages in the good and poor outcome groups. More
CD68+ tumor-associated macrophages were present in
the PO group than in either the GO group or among
normal controls (Figure 3C). CD68 immunostaining was
also more intense in the PO group than in the other
groups (Figure 3C). The analysis of CD68+ tumorassociated macrophages and IHC staining data were
verified by qRT-PCR, which demonstrated that CD68
expression in the poor outcome group was 77-fold
greater than in the good outcome group, and 224-fold
greater than in normal lymph nodes (Figure 3C, graph).
These increases suggest that a large tumor macrophage
population promotes poor clinical outcome by potentiating aggressive CD30+ tumor cells in a subset of HL
patients, and some of these CD30+ cells may express
FGF2 and SDC1.
The metastatic markers TGFβ1 and MMP9 are
overexpressed in the poor outcome group of HL patients
and by HL cell lines

Poor prognosis in HL typically correlates with the presence of tumor cells in extranodal sites distant from the
primary tumor. To investigate the metastatic potential of
HL tissues having an abundance of CD30+/FGF2+/
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Figure 2 FGF2 and SDC1 are overexpressed by HL cell lines and by CD30+ cells in the poor outcome HL patient group. (A) FGF2 and
SDC1 expression in 10 different HL cell lines (solid black bar) is represented as the normalized fold change relative to purified normal B-cells (NBC,
solid gray bar). The standard error (SE) for each cell line is indicated above each bar. See Table 2 for HL cell line characteristics. (B) Qualitative
mean intensity scores for FGF2 (solid black bar) and SDC1 (solid gray bar) from immunostained tissues in an array format consisting of 10 normal,
30 classical HL (cHL), and 18 Lymphocyte Predominant-HL (LP-HL) and 116 Non-HL (NHL) samples (y-axis). Immunostaining intensity was scored
as 0 (no staining), 1 (weak), 2 (moderate), or 3 (intense). Standard error bars of the mean are indicated. (C) FGF2, SDC1, and CD30 mRNA
expression levels in normal lymph node controls (NC, solid gray bar) and HL tissues associated with good outcome (GO, striped bar) and poor
outcome (PO, solid black bar) were analyzed by qRT-PCR. The measurements represent the fold change after normalization with the NC group.
(D) The same set of normal and HL tissues from (B) were immunostained for FGF2, SDC1, and CD30. Representative normal and stage II GO and
PO patients are shown. (E) CD20 expression in normal lymph nodes and HL tissues analyzed by immunostaining. The significance of all qRT-PCR
data comparing GO and PO is indicated (p<0.005). Scale bars represent 100 μm.

SDC1+ cells and poor clinical outcome, tissue sections
were immunostained for TGFβ1 and MMP9 expression
(Figure 4A). The HL tissues from the poor outcome
group stained intensely for MMP9 and TGFβ1 compared with the good outcome group and with normal

lymph nodes (Figure 4A). Quantitative analysis of
MMP9 and TGFβ1 gene expression in the poor outcome group showed increases of 45- and 52-fold, respectively, compared to the good outcome group (after
normalization against normal lymph nodes). The mean
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Figure 3 CD30+ cells coexpress FGF2 and SDC1 in macrophage-rich HL tissues with poor outcome. (A) Double immunofluorescent
staining showing expression of either FGF2 or SDC1 by CD30+ cells of poor outcome samples. Individual green or red fluorescence is depicted at
the bottom of each image; scale bar (white solid bar) represents 100 μm. (B) Distribution of the immunophenotypes by outcome. The mean
intensity scores for FGF2 (solid gray bar) and SDC1 (solid black bar) (y-axis) for the good outcome (GO) and poor outcome (PO) groups of HL
patients. Immunofluorescence intensity was scored as 0 (no staining), 1 (weak), 2 (moderate), or 3 (strong) for FGF2+ or FGF2- and SDC1+ or
SDC1-. The frequency (%) of expression of each combination of FGF2+/− and SDC1+/− among all tissue sections is indicated above each bar. (C)
CD68 macrophage marker expression was analyzed by immunostaining (image) and qRT-PCR (graph) in normal lymph node control (NC), good
outcome (GO), and poor outcome (PO) groups of HL patients. The fold-change in CD68 mRNA was calculated after normalization with NC.
Significance of all qRT-PCR data comparing GO and PO is indicated for (B) and (C) (p < 0.005). Scale bars represent 100 μm.

increase in MMP9 expression in the poor outcome
group was 1457-fold while the good outcome group
had levels that were increased by 26-fold compared
to normal lymph nodes, suggesting that poor outcome HL tissues have high metastatic potential. Because the HL cell lines potentially represent poor

outcome, the expression of MMP9 and TGFβ1 was
analyzed by PCR. We found that HL cell lines expressed more MMP9 and TGFβ1 than normal B
cell (Figure 4A). Double immunofluorescence analysis showed that a subpopulation of CD30+ cells
overexpressed TGFβ1 and MMP9 (Figure 4B and 4C),
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Figure 4 Metastatic markers TGFβ1 and MMP9 are overexpressed in poor outcome HL patients and by HL cell lines. (A) Protein and
mRNA expression levels of TGFβ1 and MMP9 in normal lymph node control (NC), good outcome (GO) group and poor outcome (PO) group
analyzed by immunostaining (left, images only for PO group) and qRT-PCR (right). mRNA expression is represented by fold-change (y-axis) after
normalization with the control (NC). Significance of all qRT-PCR data comparing GO and PO is indicated (p < 0.005). TGFβ1 and MMP9 are also
overexpressed by the HL cell lines (lower image of gel electrophoresis of (A)). (B) TGFβ1 and MMP9 protein coexpression in tissues from the poor
outcome HL patient group analyzed by double immunofluorescence staining for CD30, TGFβ1 and MMP9, or SDC1, TGFβ1 and MMP9. Individual
green or red fluorescence is depicted at the bottom of each image. (C) Coexpression of TGFβ1 and MMP9 by subsets of tumor cells in poor
outcome sample. (Inset of A and B) Hodgkin Reed Sternberg cells (HRS) coexpressing SDC1 and TGFβ1 or SDC1 and MMP9. Scale bar (white solid
bar) represents 100 μm.

suggesting that CD30+/TGFβ1+ and CD30+/MMP9+
cells may potentiate a metastatic environment that allows CD30+ HL tumor cells to exit the local tumor
microenvironment.

FGF2 and SDC1 are overexpressed in putative circulating
CD15+/CD30+ cells in poor outcome HL patients

To determine whether a subpopulation of CD30+ tumor
cells was potentially being shed from the local tumor

Gharbaran et al. Journal of Hematology & Oncology 2013, 6:62
http://www.jhoonline.org/content/6/1/62

Page 9 of 17

Figure 5 FGF2 and SDC1 are overexpressed in circulating CD15+/CD30+ cells from chemo-naive poor outcome HL patients. qRT-PCR
analysis of cells isolated from the buffy-coat of peripheral blood from normal donor controls (NC, striped bar), chemo- naïve (CN) good outcome
(GO, dotted) and CN poor outcome (PO, solid black bar) groups, and chemo-exposed PO group (CE, checkered bar). Expression levels are
represented as fold-change (y-axis) after normalization with normal control cells (N, solid gray bar: N denotes B cells in A and C; N denotes
monocytes, CD4 T cells, CD8 T cells, and CD19 B cells in B). (A) mRNA expression of CD30 and CD15; (B) cell-specific markers for monocytes
(CD14, CD63), T-cells (CD4,CD8), and B-cells (CD38, CD19); (C) FGF2 and SDC1. Significance of all qRT-PCR data comparing chemo-naïve GO and
chemo-naïve PO is indicated (p < 0.0001; ANOVA AND PLSD).

microenvironment and entering the circulation, we
analyzed PBL samples collected from HL patients either prior to frontline treatments (chemo-naive: CN)
or after treatment for multiple relapses (chemoexposed: CE). In baseline HL patients, qRT-PCR

results showed that cells from the poor outcome
group overexpressed CD15 and CD30 by 41-fold and
113-fold, respectively, compared to the good outcome
group after normalization with respect to purified B
cells (Figure 5A). In this analysis, the significant
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increase in marker expression seen for the poor outcome groups was eliminated in the chemo-exposed
poor outcome group (Figure 5A), suggesting that
CD15+/CD30+ cells in the circulation were killed by
chemotherapy treatments. A moderate difference in
marker expression between the CN good outcome
group and the normal control group (n=10) was
observed. To determine if the circulating cells overexpressing CD15+/CD30+ originated from other cell
types in the blood, the expression levels of established
cell-specific markers, including CD14 (monocytes,
macrophages, neutrophils, granulocytes, and dendritic
cells), CD63 (basophil activation), CD4 (helper T-cells),
CD8 (cytotoxic T cells), CD38 and CD19 (B cells) were
analyzed (Figure 5B). Among CN HL patients, compared to the good outcome group, a significant downregulation of CD14 (−7150-fold), CD63 (−966-fold),
CD4 (−1287-fold), CD8 (−2625-fold), CD38 (−253-fold)
and CD19 (−10954-fold) expression was seen for the
poor outcome group (Figure 5B). In these analyses, the
expression levels of CD8, CD38, and CD19 in chemoexposed HL patients were similar to levels in the good
outcome group of CN patients, although the downregulation of CD8 and CD19 expression was significantly lower (−125-fold for CD8 and −19085-fold
for CD19) than that in normal samples. Although the
down-regulation of CD14, CD63, CD4, and CD38
among the CN good outcome group of HL patients was
similar to normal controls, CD8 and CD19 were significantly down-regulated (CD8 by −125-fold and CD19
by −19085-fold) in the good outcome CN patients compared to normal samples (Figure 5B). The downregulation signatures of the cell markers in the CN
poor outcome group were directly opposite that of the
CD15+/CD30+ upregulation signature, suggesting that
CD15+/CD30+ cells in the CN poor outcome group
were potentially derived from circulating HL tumor
cells (Figure 5A and 5B). In these circulating cells,
FGF2 and SDC1 genes were overexpressed by 17- and
9764-fold, respectively, compared to the good outcome
group (Figure 5C). This fold-difference was reduced in
relapsing HL patients in CE group relative to the CN
good outcome group, indicating that FGF2 and SDC1
are robust baseline biomarkers for predicting clinical
outcomes for CN HL patients.

Discussion
The survival time for high risk, unfavorable cHL (early
relapse, progressive disease, primary refractory) ranges
from 0 to less than 4 years [1,25], a very poor prognosis
indeed, considering the high cure rate enjoyed by HL
patients with current standard therapy. Second line
treatments which include ASCT, and chemotherapy plus
radiation do not significantly improve the prognosis of
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this group of patients. Therefore, it is essential to identify biomarkers that can help predict, prior to treatment
which cHL patients belong in the high risk group so that
appropriate treatment options with potentially better
outcome can be implemented. The results presented
here suggest that coexpression of FGF2 and SDC1 by
CD30+ cells identify this group of patients.
Previous studies showed advanced stage, advanced age,
and bulky disease as important risk factors for poor outcome [16]. However, a contingency analysis performed
on the HL database from the Tissue Repository of the
Hackensack University Medical Center showed no association of any of these risk factors, including treatment
history (all p > 0.1) with patient outcome. These data
suggest that there may be undetermined molecular pathways that are altered in subsets of NS-cHL patients who
are predisposed to be primary refractory or experience
multiple relapses shortly after frontline treatments. To
improve the specificity of potential biomarkers that may
assist in pre-selecting poor outcome patients prior to
treatment, we used bioinformatic data mining to derive
a list of over 150 genes that represent pathways for
metastasis, apoptosis, cell proliferation, tumorigenesis
and angiogenesis. Expression screening data for these
genes showed a consistent and robust overexpression of
FGF2 and SDC1 in HL cell lines that were originally
derived from primary HRS cells isolated from extranodal
sites of refractory or relapsing HL patients. Qualitative
scoring by IHC on lymphoma tissue arrays showed that
FGF2 and SDC1 expression were indeed specific to the
HL tumor microenvironment. Further analyses by qRTPCR showed overexpression of either gene in poor
outcome samples, while additional IHC on the poor outcome samples showed regions of CD30+ cells where
FGF2 and SDC1 were strongly expressed. Double
immunofluorescence staining of samples from poor outcome biopsies showed large subsets of CD30+ cells that
expressed either FGF2 or SDC1. qRT-PCR and IHC
evaluation of CD68 expression confirmed the clinical
status of the biospecimens (poor outcome). The metastatic markers MMP9 and TGFβ1 were shown to be
overexpressed in poor outcome patient samples, including their overexpression by subsets of CD30+ cells,
suggesting metastasis by these HRS cell subsets. qRTPCR analyses of PBL showed that CD30 and CD15 (the
gene which encodes the protein that transfers fucose to
N-acetyllactosamine polysaccharides to generate fucosylated carbohydrate structures) were transcriptionally
upregulated in the untreated, poor outcome group compared to other clinical groups. Concurrently, markers
representing circulating T cells (CD4 and CD8), B cells
(CD19 and CD38), and monocytes (CD14 and CD63)
were significantly downregulated in the untreated, poor
outcome group, indicating that CD30 and CD15
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upregulation was not a consequence of their expression
by other common circulating lymphocytes. In the untreated, poor outcome group, transcription of FGF2 and
SDC1 was upregulated, most likely by CD30+/CD15+
cells. Taken together, these data indicate that in untreated, poor outcome patients, a subset of CD30+ cells
that express high levels of FGF2 and SDC1 transcripts,
perhaps HRS cells, made their way into the circulation, and may be responsible for the poor outcome
generated in primary refractory and early relapsing
NS-cHL patients.
The expression of either FGF2 or SDC1 seen in our
study is only partially consistent with previous reports.
A previous immunoblot analysis showed no expression
of FGF2 by HL cell lines KM-H2 and L428, although the
same study did detect FGF2 expression in primary HRS
cells from HL tumor biopsy samples [26]. In contrast,
our qRT-PCR data showed that FGF2 is transcriptionally
upregulated in both KM-H2 and L428 cell lines. In HL,
it appears as though FGF2 transcript translation in HRS
cells is only induced in vivo. Although perhaps not completely relevant to HL, elevated FGF2 mRNA is thought
to be involved in tumor development and progression,
as was demonstrated in acoustic neuromas [27]. Also,
there is discordance among studies of SDC1 expression
by HRS cells. Studies have reported that the percentage
of SDC1-positive HRS cells varies from 0 to 50% among
cHL cases [28-31], which is consistent for a postgerminal center origin. These differences may be due to
variations in the fixation techniques and SDC1 antibody
clones used; for example, some investigators contend
that a much higher percentage of SDC-1 positive cells is
seen in frozen material compared to formalin fixed paraffin embedded material. Our double immunofluorescence staining on fresh frozen sections from PO group
patients showed large subsets of HRS cells that costained
with anti-CD30 (clone Ber-H2) and anti-SDC1 (clone
BB4 and a polyclonal antibody from Sigma-Aldrich).
The upregulation of FGF2 and SDC1 by putative
CD30+ cells observed in our study may be the result of
unregulated, uncontrolled expression of these genes in
HRS cells from PO patients. Dysregulation of either
FGF2 or SDC1 signaling alone or together has been
associated with a variety of malignancies, including those
associated with poor prognosis. Disruption of FGF2
expression results in elevated serum FGF2 levels, which
is an independent poor prognostic factor for lymphoma,
lung cancer, and sarcoma patients [32-35]. In addition,
elevated levels of FGF2 in serum have been reported for
non-Hodgkin lymphoma (NHL) patients with poor
prognosis [36], shortened survival, and higher risk for
mortality [35]. Also in lymphoma, FGF2 overexpression
in diseased tissue biopsy samples is associated with
chemoresistance and inferior progression free and
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overall survival [37]. Kowalska et al. (2007) showed that
elevated FGF2 serum levels correlated with the erythrocyte sedimentation rate, which is a poor prognostic factor in HL [16,38]. At a molecular level, FGF2 binds to
multiple membrane bound receptors in human cancers,
including SDC1 [39], and this receptor binding can
trigger multiple signaling pathways, including those
involved in cell proliferation and survival [40,41]. Although FGF2 may not always mediate SDC1 expression
in cancers, SDC1 overexpression, at either a tissue or
serum level, has been reported for multiple tumor types
including solid tumors [42-44], lymphomas, and in a
number of lymphoproliferative disorders [29,30,45-47].
In some instances, SDC1 overexpression is an adverse
indicator for both solid and hematological malignancies
[43,44,48-50]. High levels of FGF2 and SDC1 in the
same patient have important clinical implications. Multiple myeloma patients and small cell lung cancer patients with high serum levels of soluble SDC1 and FGF2
have poor prognosis and shortened survival [51]; high
serum levels of soluble SDC1 and FGF2 are also important clinical features of high risk, primary refractory,
early relapsing cHL, and untreated poor outcome patients in our study. However, the clinical significance of
co-upregulation of SDC1 and FGF2 in serum of HL
patients has yet to be explored.
Our results also revealed that a large number of
CD68+ tumor-associated macrophages were present in
the tumor microenvironment of poor outcome tissue
samples in which the CD30+ cells overexpressed both
SDC1 and FGF2. A number of previous reports showed
that CD68+ tumor-associated macrophages are a poor
outcome marker of cHL [52-54]. Therefore, simultaneous overexpression of FGF2 and SDC1 by CD30+
cells can be used as a molecular signature to identify
high risk, poor outcome cHL patients.
The downregulation of markers representing circulating T cells, B cells and monocytes in the PBL of untreated poor outcome patients in our study is consistent
with lymphocytopenia, a negative prognostic factor in
multiple cancer types [55]. However, lymphocytopenia
alone may not adequately predict poor prognosis, and as
such better biomarkers are needed. Two recent reports
indicated that the ratio of the absolute lymphocyte count
to the absolute monocyte count (ALC/AMC) is an independent prognostic marker that can be used for stratifying high vs. low risk cHL [56-58]. Although not
demonstrated in hematological malignancies, lymphocytopenia implies a depleted immune system that lacks
adequate immune surveillance, which could play an important role in aggressive tumor metastasis. Indeed, both
lymphocytopenia and circulating tumor cells were
shown to be independent prognostic factors in the metastasis of breast cancer, carcinomas, sarcomas, and
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lymphomas; their presence is associated with an extremely poor clinical outcome [55,59]. Such a scenario
may play a role in extranodal involvement of HL, and
may identify unfavorable high risk patients irrespective
of disease stage. In such a setting, this population of HL
patients may benefit from therapies to restore immune
function prior to frontline therapy.
In some ways, the co-upregulation of FGF2 and SDC1
seen in tissue biopsies and PBL (albeit at the mRNA
level) of PO NS-cHL patients in our study may be
related to certain features of multiple myeloma. Several
studies found shared features between HRS cells and
plasma cells, including those of multiple myeloma and
their normal counterparts, despite the differences in
disease behavior [30,60-62]. Like plasma cells, HRS cells
typically not only lack expression of B-cell surface
markers, but they are also the only other lymphocytes
that occasionally express SDC1 [30,60-63]. Although B
lymphocyte–induced maturation protein 1 (Blimp-1),
which is a transcription factor required for plasma cell
differentiation [62], was not part of our study, a fraction
of HRS cells also express this protein. There is the possibility that subsets of, if not all, HRS cells and multiple
myeloma plasma cells share a common ancestral precursor [64], although the majority of HRS cells shed
their plasma cell signature (e.g., SDC1 expression) [62].
Those HRS cells that continue to express SDC1 are
perhaps more aggressive than their SDC1 negative counterparts, thus contributing to the aggressive nature of
poor outcome cHL, and producing the sort of unfavorable prognosis that is typical of primary refractory and
early relapsing cHL patients. Of additional interest is the
coexistence of HRS cells with aggressive multiple myeloma [65], or their appearance after treatment of multiple myeloma [66].
Our data also showed that the established metastatic
markers MMP9 and TGFβ1 were overexpressed by
subsets of CD30+/FGF2+/SDC1+ cells in tissue biopsy
samples from PO patients. HRS cells produce activated
TGFβ1 in primary tumor tissues, predominantly in
nodular sclerosing HL [67], while MMP9 overexpression
is associated with adverse clinical outcomes in HL [68].
As such, HRS cells that harbor the FGF2+/SDC1+
immunophenotype and express both MMP9 and TGFβ1
are the cells most likely to be shed from the tumor
microenvironment. Thus, the molecular interplay of
FGF2, SDC1, MMP9, and TGFβ1 may play a role in HL
metastasis.
Finally, our results revealed that subsets of circulating cells transcriptionally upregulate CD30, CD15,
FGF2, and SDC1 in the untreated poor outcome
group. The main subset here could be putative HRS
cells or some other variant of these neoplastic cells
that are SDC1+/FGF2+ and overexpress MMP9 and
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TGFβ1. While characteristic HRS cells are not typically
found in PBL, the metastatic and hematogenous spread
of HL is suspected in cases diagnosed with extralymphatic and extranodal involvement [15]. Therefore,
a variant of HRS cells that do not exhibit the classical
phenotype displayed by nodal HRS may be in the circulation of untreated poor outcome patients, perhaps due
to a difference in the microenvironment (PBL versus
lymph node). In other settings, either normal cells or
circulating tumor cells may express important transcripts that are translated only when the appropriate
microenvironment prevails, and thus the cell phenotype
may also change. This concept is evident during development during which the zygote produces maternal
RNAs that are later translated into functional proteins
at each stage during embryogenesis. At least two studies
of HL patient subsets suggest a similar occurrence. In
vitro experiments by Zucker-Franklin and colleagues
(1983) and Sitar et al. (1994) showed that RS-like cells
can be generated from cultured peripheral mononuclear
blood cells (PMBC) from HL patients [69,70]. ZuckerFranklin et al. observed RS-like cells only in HL samples
(including early stage disease), and not PMBC of NHL,
mycosis fungoides, or of control samples, suggesting
that giant cell formation from PMBC is limited to HL
cases. Sitar and colleagues showed that 10% of the giant
RS-like cells were CD30+ and EBV-positive [70].

Conclusions
Our study used bioinformatics analysis to identify biomarkers that could be helpful in identifying HL patients
who are predisposed to a poor outcome, and could be
helpful in directing these patients to the optimal treatment regimen. In poor prognosis HL patients, we found
small subsets of circulating CD30+/CD15+ cells that
express FGF2 and SDC1; these proteins may be appropriate biomarkers for HL prognosis.
Methods and materials
Bioinformatics

The BioXM software platform (Sophic Alliance, Rockville,
MD) was used to mine potential biomarkers for
Hodgkin’s lymphoma using the National Cancer Institute (NCI) Cancer Gene Index, which contains 7,000
cancer genes and 2,200 biomarker genes. These genes
were annotated and validated from 18 million Medline
abstracts and 24,000 Hugo genes from over 80 databases, using a combination of algorithmic methods
(Biomax Informatics, Munich, Germany) that included
natural language processing (NLP), Biomarker Role
Codes, the NCI Cancer Thesaurus, and Karp’s Evidence
Codes [23]. The identification of potential biomarkers
was performed by initiating queries on BioXM with a
combination of search terms including Hodgkin’s
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disease, lymphoma, cancer, biomarker, overexpression,
up-regulation or down-regulation, and differentiallyexpressed. The bioinformatics-guided search generated
151 potential HL biomarkers (Table 2).
Cell lines and cell culture

The Hodgkin’s lymphoma cell lines KM-H2, HD-MY-Z,
HDLM-2, L-591, and SUP-HD1 were obtained from the
German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). L-428, L-1236, and L-540
cells were generous gifts provided by Dr. Volker Diehl
(University of Cologne, Germany). U-H01 and DEV cells
were kind gifts from Dr. S. Brüderlein (University
Hospital Ulm, Germany) and Dr. Debora De Jong
(Netherlands), respectively. KM-H2, L-428, HD-MY-Z,
and L-1236 cells were cultured in 90% RPMI 1640
supplemented with 10% fetal bovine serum (FBS). SUPHD1 cells were grown in 80% McCoy’s 5A medium
containing 20% FBS. HDLM-2, L-540, and L-591 cells
were grown in 80% RPMI 1640 supplemented with 20%
FBS. U-H01 cells were grown in Iscove’s MDM and
RPMI 1640 (4:1) supplemented with 20% FBS. All
culture media contained 2 mM L-glutamine, penicillin
(100 U/ml), and streptomycin (0.1 mg/ml). Cultures
were maintained at 37°C with 5% CO2. The clinical
characteristics of each cell line were previously documented and are presented in Table 3. DEV, KM-H2, and
SUP-HD1 cells were derived from relapsing cases.
HD-MY-Z, L1236, L428, and U-H01 cells were from
refractory patients.
RNA isolation and cDNA synthesis

Total RNA from cell lines and peripheral blood (PBL)
of HL patients was isolated using Trizol (Invitrogen,
Carlsbad, CA). RNA from archived FFPE tissue sections

Table 3 Characteristics of HL cell lines
Cell line
DEV
HDLM2
HD-MY-Z

Clinical characteristic

Anatomic site of primary cell

relapse

Pleural fluid

n/a

Pleural fluid

refractory

Bone marrow

KM-H2

relapse

Pleural fluid

L1236

refractory/relapse

Peripheral blood

L428

refractory

Pleural fluid

L540

n/a

Bone marrow

L591

n/a

Pleural fluid

SUP-HD1
U-H01

relapse

Pleural fluid

refractory

Pleural fluid

A review of the literature showed that all established HL cell lines were
derived from primary malignant CD30+ cells isolated from extra-nodal sites:
pleural fluid, bone marrow, and peripheral blood. No cell lines to date have
been raised from primary HRS cells isolated from lymph nodes.
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was extracted using RNeasy (Qiagen, CA) according to
the manufacturer’s instructions. The RNA concentration was spectrophotometrically determined at A260
(ThermoElectro Corporation). Total RNA integrity was
checked by resolution on a 2% agarose gel under denaturing conditions. cDNA was generated using the
SuperScript III RT First-Strand cDNA Synthesis Kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Oligo-dT primers were used to generate cDNA from cell lines and PBL-derived RNA, and
random hexamers were used for generating cDNA from
RNA obtained from FFPE sections.
Polymerase chain reaction (PCR)

Primer sets used for each gene were generated using
online primer tools (University of Massachusetts;
http://biotools.umassmed.edu/bioapps/primer3_www.
cgi) (Table 2). Primers were designed to have lengths
of 18 to 27 nt with Tm = 60°C and 45 to 65% GC
content, and were synthesized by a custom primer
service provided by Invitrogen. Each primer pair was
confirmed to generate a single discrete band by endpoint PCR (BioRad DNA Engine Peltier Thermal Cycler) using cDNAs generated from normal spleen
tissue. End-point PCR conditions consisted of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and primer extension at 72°C for 1 minute. The
primer pairs were designed to generate a PCR fragment of
150–170 bp for cell line- and PBL-derived cDNA, and
70–100 bp for FFPE-derived cDNA (Table 4). The PCR
products were resolved on a 2% agarose gel and visualized with ethidium bromide staining using a BioRad
Imager. For qRT-PCR, each reaction consisted of 43 ng
cDNA, 10 mmole primers and 10 μl 2X Power SYBR
Green PCR Master Mix (Applied Biosystems, Foster City,
CA) in a final volume of 20 μl, which was placed in a
MicroAmp Fast Optical 96-Well Reaction Plate designed
for use with the ABI7900 PCR system (Applied Biosystems). The reaction was performed using the standard
mode (initial denaturation at 95°C for 10 minutes followed
by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute). Each qRT-PCR reaction was done in triplicate,
and each data set was analyzed with ABI7900 software.
The amount of target mRNA was normalized to the expression levels of the housekeeping gene GAPDH. For
cell lines, CD19 was used as control. For PBL analysis,
the expression levels of CD14/63, CD38/19, and CD4/8
were compared against their expression in monocytes,
CD19+ B cells, helper T cells, and cytotoxic T cells, respectively, of healthy donors (Miltenyi Biotech). Pooled
normal cDNA (n=20) was used as a control for gene
expression analysis of FFPE tissue-derived cDNA. The
ΔΔCt method was used to calculate the fold-change
relative to controls.
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Table 4 Primer sets for each gene used in this study
Genes

Forward sequence

Reverse sequence

A. Primer sets used on PBL samples.
GAPDH

catggcctccaaggagtaag

aggggtctacatggcaactg

CD4

atgtggcagtgtctgctgag

cctagcccaatgaaaagcag

CD8

cagagctacccgcagagttc

ctccaaccctgacttgctgt

CD30

ccaacttagctgtcccctga

ctgggaccaatgctgttctc

CD15

gcaggtgggactttgttgtt

ccaaggacaatccagcactt

CD19

ttctgcctgtgttcccttg

cacgttcccgtactggttct

CD38

agatctgagccagtcgctgt

aaaaaggcttccgtctctgg

CD14

gagctcagaggttcggaaga

ttcggagaagttgcagacg

CD63

aaccacactgcttcgatcct

aatcccacagcccacagtaa

FGF2

tgctcagcagtcaccatagc

cttgaggtggaagggtctcc

SDC1

cttcacactccccacacaga

ggccactacagccgtattct

B. Primer sets used on FFPE tissues.
GAPDH

cctcaacgaccactttgtca

ccctgttgctgtagccaaat

TGFβ

gtacctgaacccgtgttgct

cacgtgctgctccactttta

MMP9

ggcgctcatgtaccctatgt

gccattcacgtcgtccttat

CD30

gaagctccacctgtgctacc

ggtctggaatccacaagctc

CD68

tgacacccacggttacagag

gtggttttgtggctcttggt

SDC1

taggacctttccaccacagc

gaggctgcttcagtttggag

FGF2

tgaggctgagaggtcaaggt

ctctgttgcctaggctggac

Selection of clinical samples

The selection criteria of peripheral blood samples were
based on the response to front line therapy (Table 1).
Twenty five nodular sclerosing cHL patient samples
registered in the database at the Hackensack University Medical Center were categorized into: 1) good
outcome chemo-naïve, untreated, relapse-free/diseasefree > 4 years (n=12); 2) poor outcome chemo-naïve
(untreated), primary refractory or early relapse (n=7); 3)
chemo-exposed (pretreated), multiple relapses (n=6).
Formalin-fixed, paraffin-embedded (FFPE), and fresh
frozen (FF) lymph nodes from different HL stages and
subtypes were obtained from Thomas Jefferson University,
the Tissue Repository of the Hackensack University
Medical Center, and Proteogenex (Culver City, CA).
Biospecimens with the relevant clinical characteristics
were grouped into good outcome (GO, relapse free/
disease free > 4 years, n=20) and poor outcome (PO,
shortened survival— death 2 to 3 years after diagnosis).
A lymphoma tissue array was obtained from US Biomax
(Rockville, MD).
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agent (Amresco, Solon, OH) for 10 minutes each, then
sequentially hydrated in 100%, 90%, 80%, 70%, and 50%
ethanol followed by equilibration in PBS for 5 minutes
each. All antigen retrievals were carried out in a 95°C
water bath for 20–30 minutes (depending on the
antigen) using high pH (pH 9) buffer (DAKO) for FGF2,
SDC1, MMP9, and CD68, or low pH (pH 6) buffer
(DAKO) for CD30, TGFβ1, and CD20. The sections
were cooled for 20 minutes at room temperature and
then washed twice with PBS for 5 minutes. Endogenous
peroxidases were quenched by incubating the sections in
3% H2O2 solution in PBS for 10 minutes followed by
rapid washes in PBS at room temperature. A hydrophobic PAP pen (Vector Labs, Burlingame, CA) was
used to make a dam around the sections, which were
then blocked at room temperature for 2 hours with 1%
BSA containing 5% swine serum in PBS, followed by
overnight incubation with primary antibodies at 4°C.
Monoclonal antibodies for CD30 (clone Ber-H2, DAKO),
SDC1 (clone BB4, Abd Serotec), CD68 (clone PG-M1,
DAKO), and CD20 (clone L26, DAKO) were used at
dilutions of 1:20, 1:40, 1:50, and 1:100, respectively.
Rabbit polyclonal antibodies for FGF2 (Santa Cruz),
TGFβ1 (Santa Cruz), and MMP9 (DAKO) were used at
dilutions of 1:200, 1:200, and 1:100, respectively. Stained
sections were washed three times in PBS/0.1% Tween-20
for 5 minutes each and then once in PBS for 5 minutes.
Signal detection was carried out using an LSAB kit
according to the manufacturer’s instructions (DAKO),
with minor modifications. Briefly, sections were incubated in Biotinylated Link for 30 minutes at room
temperature and washed three times in 0.1% PBST
for 5 minutes each. Sections were then incubated in
streptavidin-HRP for 30 minutes and washed as described above. Signals were visualized by incubating
the slides in a solution of 1 ml substrate buffer with
1 drop chromogen, and immediately rinsed in tap water.
The sections were counterstained with hematoxylin
(Vector Labs) for 22 seconds and immediately washed in
tap water before mounting with Aqua Mount (Vector
Labs). Photomicrographs of stained tissues were generated
with an Axio Cam MRc camera coupled to an Axio
Imager Microscope (Carl Zeiss, Thornwood, NY). Positive
control slides included tonsil for CD20, CD68, and SDC1,
and ALCL for CD30 (on lymphoma array). For qualitative
scoring, no staining was assigned a score of 0, weak staining 1, moderate staining 2, and intense staining, 3.
Immunofluorescence

Immunohistochemistry

FFPE and fresh frozen lymph nodes from different stages
and subtypes of HL were purchased from US Biomax
and Proteogenex. FFPE sections (5 μm) mounted on
slides were dewaxed twice with Histochoice clearing

Double immunofluorescence analysis was performed
on 5 μm FFPE and OCT-embedded 8 μm fresh frozen
(FF) tissue sections that were mounted on positivelycharged frosted slides (Histoserv, Germantown, MD).
FFPE sections were processed similarly to the preparation
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used for IHC. OCT-embedded FF sections were thawed
at room temperature for 20 minutes, rinsed briefly in
PBS, and then fixed in 3.7% formaldehyde (Electron
Microscopy Sciences, PA) for 20 minutes at room
temperature. The remaining steps for immunofluorescence signal detection were carried out using a TSA
Detection system (Invitrogen) according to the manufacturer’s instructions. Monoclonal and polyclonal signals were detected with Alexa Fluor 488 and Alexa
Fluor 546, respectively. The antibodies used were the
same as for IHC, except that a SDC1 rabbit polyclonal
antibody (Sigma-Aldrich) was used for CD30-SDC1
double staining. Slides were counterstained with Hoechst
33342, visualized with a Leica DMI 6000B inverted
microscope, and analyzed using Leica MM AF software,
version 1.5 (Leica Microsystems). Slides were independently reviewed and verified by two pathologists.
Statistics

Data analyses were performed using SAS 9.1.3, StatView
5, or JMP 4. Contingency and likelihood ratio analyses
were used to determine the independence of staging
and prognosis. The mean fold-change for each sample
was determined from triplicates of the qRT-PCR data.
Analysis of variance (ANOVA) and F statistics were
used to determine differences between the means of the
poor outcome group and other outcome groups. Fisher’s
protected least significant difference (PLSD) was used
to determine pair-wise significant differences between
group means.

Keypoints
FGF2 and SDC1 overexpression by circulating CD15+/CD
30+ cells is associated with poor outcome in Hodgkin
Lymphoma.
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